UNSPSC 51281642: Capreomycin iib

This classification denotes an antitubercular agent and aminoglycoside antibiotic with the molecular formula C19H32N12O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K630580G1N, chemically known as cyclo((2s)-2-amino-.beta.-alanyl-l-alanyl-3-amino-l-alanyl-(2z)-3-((aminocarbonyl)amino)-2,3-didehydroalanyl-(2s)-2-((4r)-2-amino-3,4,5,6-tetrahydro-4-pyrimidinyl)glycyl), but more generally known as capreomycin iib, which bears US NIH Compound Identifier 3034237.

European Medicines Agency schedules capreomycin iib or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01028MIG. Most nations, for tariff purposes, schedule capreomycin iib under HS 29419000. SMILES: C[C@H]1C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCN=C(N2)N)CN.

UNSPSC 51281642 Capreomycin iib is a Commodity code that nominally identifies a specific anti-tuberculosis pharmaceutical, yet recent state and local procurement activity tagged under this code does not reflect the purchase of capreomycin itself. Instead, opportunities posted against this code span a wider range of pharmaceutical, medical supply, and pharmacy benefit program work — including naloxone procurement, medical and first aid supplies for emergency response, generic multi-source pharmaceuticals and OTC products through cooperative purchasing vehicles, and strategic market intelligence gathering on direct-to-manufacturer prescription programs. The mismatch between the code's nominal scope and the actual work being solicited suggests either a cataloging error in how these opportunities were tagged or a broader interpretation of the code's application to pharmaceutical-related state and local buying. State and local governments using this code include county health departments (Seminole County, Florida), municipal fire departments (City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP serving multiple states including Oregon).

Recent activity appears concentrated in Florida and Minnesota, with representation from Texas and other MMCAP member jurisdictions. The Seminole County IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The City of Tampa's IFB for medical and first aid supplies (26P00145, due March 13, 2026) encompassed 169 line items for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000 and a 5% bid discount available to certified Small Local Business Enterprises. The Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) established contracts spanning multiple states, requiring vendor compliance with cGMP, DSCSA, and relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson. The Texas HHS Commission issued an RFI (HHS0017013, due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs for state pharmacy benefits, signaling potential future formal solicitation activity in pharmaceutical distribution and contracting.